Clinical trials: Prostate
Prostate Cancer, Prostate Carcinoma
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation
This is a multi-center, single-arm, prospective study to assess the efficacy and safety of Olaparib in men with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) who carried homologous recombination repair…
- Conditions
- Prostate Cancer, Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- PROspect (NCT05262608)
- Testing
- Olaparib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Prostate Cancer
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome
Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.
- Trial name
- NCT03383107
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Prostatic Neoplasms
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
- Trial name
- NCT02381236
- Testing
- G-202
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GenSpera, Inc.
Prostate Cancer
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer.
- Trial name
- NCT00345293
- Testing
- autologous dendritic cell vaccine (DC/PC3)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rockefeller University
Localized T1-T2 Prostate Cancer
SpaceOAR System RWS in China
This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting…
- Trial name
- NCT05407714
- Testing
- SpaceOAR Treatment
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body.
- Trial name
- DAROL (NCT04122976)
- Testing
- Darolutamide(Nubeqa, BAY1841788)
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 805 people
- Sponsor
- Bayer
Osteoporosis
Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Multi-center,double blind randomized phase III placebo controlled study in 250 men with histologically proven prostate cancer with out bone metastases who are beginning ADT therapy and who will receive concomitant treatment with…
- Trial name
- NCT00236002
- Testing
- Alendronate
- Volunteers
- 182 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Efavirenz in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate…
- Trial name
- FAVE (NCT00964002)
- Testing
- efavirenz
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Bergonié
Benign Prostatic Hyperplasia, Bladder Outlet Obstruction
Urinary CTGF in Benign Prostatic Obstruction
Benign prostatic obstruction (BPO) is one of the most common causes of bladder outlet obstruction (BOO) and may lead to progressive structural and functional alterations in the bladder over time.
- Conditions
- Benign Prostatic Hyperplasia, Bladder Outlet Obstruction, Lower Urinary Tract Symptom
- Trial name
- NCT07416981
- Volunteers
- 50 people
- Sponsor
- Tarik Emre Sener
Prostate Cancer, Hypoxia
Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
Due to the rapid growth, tumour demand for oxygen is often higher than what can be delivered by the newly forming blood vessels.
- Trial name
- HYPROGEN (NCT05702619)
- Testing
- Optional non-IMP pimonidazole, CT-guided Bone Biopsy, TRUS-guided Targeted Transperineal Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic Prostate Cancer, Recurrent Prostate Cancer
Impact of Atorvastatin on Prostate Cancer Progression During ADT
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- ESTO2 (NCT04026230)
- Testing
- Atorvastatin 80mg
- Where
- 10 sites in Denmark, Estonia and 2 more
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Metastatic Castrate-Resistant Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
This study consists of two phases: Dose Escalation (Phase 1b) and Dose Expansion (Phase 2) The Dose Escalation phase will characterize the safety, tolerability, and determine the maximum tolerated dose (MTD) of alobresib as a…
- Trial name
- NCT02607228
- Testing
- Alobresib, Enzalutamide
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
Prostate Cancer
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer
In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day.
- Trial name
- NCT05522907
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments.
- Trial name
- NCT01845792
- Testing
- Cabazitaxel with Abiraterone Acetate, Cabazitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer, Polygenic Risk Score
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric…
- Trial name
- PRS (NCT06398639)
- Testing
- Polygenic Risk Score (PRS)
- Where
- 5 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Adam S. Kibel, MD
Prostatic Neoplasms
Men at High Genetic Risk for Prostate Cancer
Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated…
- Trial name
- NCT03805919
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Benign Prostatic Hyperplasia
Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)
Purpose: To evaluate the efficacy of prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH) and refractory lower urinary tract symptoms (LUTS) in decreasing the volume of the prostate gland.
- Trial name
- NCT02167919
- Testing
- Microspheres
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Breast Cancer, Autoimmune Disease
Continuation of Follow-up of DES-Exposed Cohorts
Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery.
- Conditions
- Breast Cancer, Autoimmune Disease, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT00340600
- Where
- United States
- Volunteers
- 10,805 people
- Sponsor
- National Cancer Institute (NCI)